MAIA Biotechnology Inc. (MAIA)

AI Score

Unlock

1.58

-0.09 (-5.39%)

At close: Mar 25, 2025, 3:59 PM

1.57

-0.64%

Pre-market: Mar 26, 2025, 07:07 AM EDT

-5.39% (1D)

Bid	1.52
Market Cap	43.56M
Revenue (ttm)	n/a
Net Income (ttm)	-28.4M
EPS (ttm)	-1.34
PE Ratio (ttm)	-1.18
Forward PE	-1.38
Analyst	n/a

Ask	1.69
Volume	80,938
Avg. Volume (20D)	289,020
Open	1.64
Previous Close	1.67
Day's Range	1.56 - 1.65
52-Week Range	1.46 - 5.99
Beta	0.21

About MAIA

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 28, 2022

Employees 13

Stock Exchange AMEX

Ticker Symbol MAIA

Website https://www.MAIABiotech.com

Full Company Profile

Why Price Moved

1 month ago

-1.07%

MAIA Biotechnology shares are trading lower after ... Unlock content with Pro Subscription

1 month ago

+5.82%

MAIA Biotechnology shares are trading higher after the company announced updated data from its THIO-101 Phase 2 clinical trial evaluating THIO.

News

1 day ago · businesswire.com

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.

6 days ago · businesswire.com

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug.

1 week ago · businesswire.com

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO.

3 weeks ago · businesswire.com

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.